83 FR 209 pgs. 54355-54356 - Endo Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 10 New Drug Applications
Type: NOTICEVolume: 83Number: 209Pages: 54355 - 54356
Pages: 54355, 54356Docket number: [Docket No. FDA-2018-N-3647]
FR document: [FR Doc. 2018-23528 Filed 10-26-18; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: Food and Drug Administration
Official PDF Version: PDF Version
[top]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2018-N-3647]
Endo Pharmaceuticals, Inc., et al.; Withdrawal of Approval of 10 New Drug Applications
AGENCY:
Food and Drug Administration, HHS.
ACTION:
Notice.
SUMMARY:
The Food and Drug Administration (FDA or Agency) is withdrawing approval of 10 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.
DATES:
Approval is withdrawn as of November 28, 2018.
FOR FURTHER INFORMATION CONTACT:
Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601.
SUPPLEMENTARY INFORMATION:
[top] The applicants listed in the table have informed FDA that these drug products are no longer marketed and have requested that FDA withdraw approval of the applications under the process in §?314.150(c) (21 CFR 314.150(c)). The applicants have also, by their requests, waived their opportunity for a hearing.
| Application No. | Drug | Applicant |
|---|---|---|
| NDA 009165 | Delatestryl (testosterone enanthate) Injection, 200 milligrams (mg)/milliliter (mL) | Endo Pharmaceuticals, Inc., 1400 Atwater Dr., Malvern, PA 19355. |
| NDA 010417 | Xylocaine (lidocaine hydrochloride (HCl)) 4% Topical Solution/Sterile Injection | Fresenius Kabi, USA, LLC, Three Corporate Dr., Lake Zurich, IL 60047. |
| NDA 016297 | Xylocaine (1.5% lidocaine HCl with dextrose 7.5%) Spinal Injection, 2 mL ampules | Do. |
| NDA 016724 | Norinyl 1+80 (mestranol and norethindrone) 21-Day Tablets, 0.08 mg/1 mg | GD Searle LLC, a subsidiary of Pfizer Inc., 235 East 42nd St., New York, NY 10017. |
| NDA 016725 | Norinyl 1+80 (mestranol and norethindrone) 28-Day Tablets, 0.08 mg/1 mg | Do. |
| NDA 019217 | Sodium Chloride 0.9% Injection USP in Plastic Container, 9 mg/mL | ICU Medical, Inc., 600 N. Field Dr., Lake Forest, IL 60045. |
| NDA 019222 | Dextrose 5% Injection USP in Plastic Container, 50 mg/mL | Do. |
| NDA 203098 | Testosterone Gel, 2.5 mg/1.25 grams (g), 25 mg/2.5 g, 50 mg/5 g | Perrigo Co., U.S. Agent for Perrigo Israel Pharmaceuticals Ltd., 3490 Quebec Ave. North, Minneapolis, MN 55427. |
| NDA 204031 | Xartemis XR (oxycodone HCl and acetaminophen) Extended-Release Tablets, 7.5 mg/325 mg | Mallinckrodt Inc., 675 McDonnell Blvd., Hazelwood, MO 63042. |
| NDA 205777 | Targiniq ER (naloxone HCl and oxycodone HCl) Extended-Release Tablets, 5 mg/10 mg, 10 mg/20 mg, and 20 mg/40 mg | Purdue Pharma, LP, One Stamford Forum, Stamford, CT 06901-3431. |
Therefore, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn as of November 28, 2018. Introduction or delivery for introduction into interstate commerce of products without approved new drug applications violates section 301(a) and (d) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 331(a) and (d)). Drug products that are listed in the table that are in inventory on November 28, 2018 may continue to be dispensed until the inventories have been depleted or the drug products have reached their expiration dates or otherwise become violative, whichever occurs first.
Dated: October 23, 2018.
Leslie Kux,
Associate Commissioner for Policy.
[FR Doc. 2018-23528 Filed 10-26-18; 8:45 am]
BILLING CODE 4164-01-P